Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma.

Literature DB >> 1483923

Inactivation of the p53 gene is not required for tumorigenesis of medullary thyroid carcinoma or pheochromocytoma.

I Yana¹, T Nakamura, E Shin, K Karakawa, H Kurahashi, Y Kurita, T Kobayashi, T Mori, I Nishisho, S Takai.

Abstract

A polymerase chain reaction (PCR)-mediated RNase protection analysis was performed to detect subtle genetic alterations of p53 in medullary thyroid carcinoma (MTC) and pheochromocytoma. None of the 30 pheochromocytomas showed abnormal RNase protection patterns. Only one of 32 MTCs showed an abnormal pattern, and subsequent DNA sequencing of the PCR product revealed that it had a G to C transversion in codon 49 that resulted in a change from aspartic acid to histidine. However, this was a sporadic MTC with no specific clinicopathological characteristics. On the basis of a previous report that genes on chromosome 17p were not deleted in MTCs and were relatively infrequently deleted in pheochromocytomas, our results suggest that the p53 gene is not involved in tumorigenesis of MTC or pheochromocytoma.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：
Ribonucleases

Year: 1992 PMID： 1483923 PMCID： PMC5918706 DOI： 10.1111/j.1349-7006.1992.tb02730.x

Source DB: PubMed Journal: Jpn J Cancer Res ISSN： 0910-5050

23 in total

1. Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma.

Authors: J Toguchida; T Yamaguchi; S H Dayton; R L Beauchamp; G E Herrera; K Ishizaki; T Yamamuro; P A Meyers; J B Little; M S Sasaki
Journal: N Engl J Med Date: 1992-05-14 Impact factor: 91.245

2. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors: S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal: Cancer Res Date: 1990-12-01 Impact factor: 12.701

3. Mutations in the p53 gene occur in diverse human tumour types.

Authors: J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal: Nature Date: 1989-12-07 Impact factor: 49.962

4. Loss of heterozygosity suggests multiple genetic alterations in pheochromocytomas and medullary thyroid carcinomas.

Authors: S Khosla; V M Patel; I D Hay; D J Schaid; C S Grant; J A van Heerden; S N Thibodeau
Journal: J Clin Invest Date: 1991-05 Impact factor: 14.808

5. Close linkage of MEN2A with RBP3 locus in Japanese kindreds.

Authors: M Yamamoto; S Takai; T Miki; K Motomura; M Okazaki; I Nishisho; H Tateishi; A Miyauchi; T Honjo; A J Pakstis
Journal: Hum Genet Date: 1989-06 Impact factor: 4.132

6. Deletion of genes on chromosome 1 in endocrine neoplasia.

Authors: C G Mathew; B A Smith; K Thorpe; Z Wong; N J Royle; A J Jeffreys; B A Ponder
Journal: Nature Date: 1987 Aug 6-12 Impact factor: 49.962

7. Consistent association of 1p loss of heterozygosity with pheochromocytomas from patients with multiple endocrine neoplasia type 2 syndromes.

Authors: J F Moley; M B Brother; C T Fong; P S White; S B Baylin; B Nelkin; S A Wells; G M Brodeur
Journal: Cancer Res Date: 1992-02-15 Impact factor: 12.701

8. Loss of heterozygosity on chromosome 17p13 in breast carcinomas identifies tumors with high proliferation index.

Authors: G R Merlo; T Venesio; A Bernardi; L Canale; P Gaglia; D Lauro; A P Cappa; R Callahan; D S Liscia
Journal: Am J Pathol Date: 1992-01 Impact factor: 4.307

9. Deletion mapping on the distal third region of chromosome 1p in multiple endocrine neoplasia type IIA.

Authors: K P Yang; C V Nguyen; S G Castillo; N A Samaan
Journal: Anticancer Res Date: 1990 Mar-Apr Impact factor: 2.480

10. Loss of heterozygosity on chromosome 1p in thyroid adenoma and medullary carcinoma, but not in papillary carcinoma.

Authors: K Kubo; K Yoshimoto; Y Yokogoshi; M Tsuyuguchi; S Saito
Journal: Jpn J Cancer Res Date: 1991-10

10 in total

1. Possible Relation of p53 and mdm-2 Oncoprotein Expression in Thyroid Carcinoma: A Molecular-Pathological and Immunohistochemical Study on Paraffin-Embedded Tissue.

Authors: Kurt W. Schmid; Agnes Bankfalvi; Swantja Mucke; Dietmar Ofner; Kristina Riehemann; Soren Schroder; Andrea Stucker; Martin Totsch; Barbara Dockhorn-Dworniczak
Journal: Endocr Pathol Date: 1996 Impact factor: 3.943

2. The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas.

Authors: K Y Lam; C Y Lo; N M Wat; J M Luk; K S Lam
Journal: J Clin Pathol Date: 2001-06 Impact factor: 3.411

3. p53 abnormalities are rare events in neuroendocrine (Merkel cell) carcinoma of the skin. An immunohistochemical and SSCP analysis.

Authors: M Schmid; K Janssen; B Dockhorn-Dworniczak; D Metze; B W Zelger; T A Luger; K W Schmid
Journal: Virchows Arch Date: 1997-03 Impact factor: 4.064

4. Bcl-2 and c-Myc, but not bax and p53, are expressed during human medullary thyroid tumorigenesis.

Authors: D G Wang; W H Liu; C F Johnston; J M Sloan; K D Buchanan
Journal: Am J Pathol Date: 1998-06 Impact factor: 4.307

Review 5. Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors: Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal: Endocr Pathol Date: 2003 Impact factor: 3.943

6. Concurrent Pheochromocytoma, Paraganglioma, Papillary Thyroid Carcinoma, and Desmoid Tumor: A Case Report with Analyses at the Molecular Level.

Authors: Lucio Scopsi; Luca Cozzaglio; Paola Collini; Maria Gullo; Italia Bongarzone; Monica Giarola; Paolo Radice; Leandro Gennari
Journal: Endocr Pathol Date: 1998 Impact factor: 3.943

7. Exomic sequencing of medullary thyroid cancer reveals dominant and mutually exclusive oncogenic mutations in RET and RAS.

Authors: Nishant Agrawal; Yuchen Jiao; Mark Sausen; Rebecca Leary; Chetan Bettegowda; Nicholas J Roberts; Sheetal Bhan; Allen S Ho; Zubair Khan; Justin Bishop; William H Westra; Laura D Wood; Ralph H Hruban; Ralph P Tufano; Bruce Robinson; Henning Dralle; Sergio P A Toledo; Rodrigo A Toledo; Luc G T Morris; Ronald A Ghossein; James A Fagin; Timothy A Chan; Victor E Velculescu; Bert Vogelstein; Kenneth W Kinzler; Nickolas Papadopoulos; Barry D Nelkin; Douglas W Ball
Journal: J Clin Endocrinol Metab Date: 2012-12-21 Impact factor: 5.958